Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inteliphage (formerly Vésale Bioscience) is a personalized phage therapy platform designed to treat antimicrobial-resistant (AMR) bacterial infections. The platform utilizes a proprietary automated diagnostic tool called the Phagogram to rapidly identify the most effective combination of bacteriophages from a GMP-certified library for a specific patient's infection. These selected bacteriophages are then formulated as tailored magistral preparations. The mechanism of action involves the bacteriophages specifically binding to, infecting, and lysing pathogenic bacteria, often in synergy with conventional antibiotics to overcome resistance. This precision medicine approach represents an innovative modality for treating bacterial infections where standard antibiotic treatments have failed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Inteliphage.